Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETLAS-2 trial of tadalafil in cerebral small vessel disease after stroke
2020-002329-27Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cerebral Small Vessel Disease (CSVD) and ischemic stroke comparing Tadalafil with Placebo (2 arms). Primary endpoints: Drop-out rate and Proportion achieving target dose. Started May 2020; status: completed.
02
Drugs
tadalafil
03
Conditions
Cerebral Small Vessel Disease (CSVD)ischemic stroke
Beyond the preview
Go deeper on 2020-002329-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002329-27.